Director Freda C. Lewis-Hall filed a Form 3 Initial Statement of Beneficial Ownership with the SEC on October 26, 2026, disclosing her initial holdings in Helus Pharma Inc. as of the event date of October 13, 2026.

Key Highlights

  • Reporting person: Freda C. Lewis-Hall, disclosed as a Director of Helus Pharma Inc.
  • Direct common share ownership: 100,000 common shares held directly as of October 13, 2026.
  • Stock options: 25,000 options to purchase common shares, held indirectly through Intelmed, LLC, with an exercise price of $5.99 (converted from C$8.39 at C$1.40 = US$1.00), expiring October 1, 2035, vesting quarterly over two years commencing December 31, 2025.
  • Restricted Share Units: 25,000 RSUs held directly, each representing the right to receive one common share, vesting November 20, 2026.
  • Indirect holding vehicle: Intelmed, LLC, described in the filing as a limited liability company owned and controlled by the reporting person.

Lewis-Hall's Initial Beneficial Ownership in Helus Pharma

According to the filing, Freda C. Lewis-Hall submitted her initial statement of beneficial ownership in connection with her role as a Director at Helus Pharma Inc. (NASDAQ:HELP). The event date requiring the statement was October 13, 2026, and the form was signed and filed on October 26, 2026. The filing covers both direct and indirect holdings across three categories of securities.

The filing discloses that Lewis-Hall directly owns 100,000 common shares of Helus Pharma Inc. In addition, she holds 25,000 stock options indirectly through Intelmed, LLC, a limited liability company the filing states is "owned and controlled by the reporting person." Those options carry an exercise price of $5.99 per share, which the filing notes was converted from a Canadian exercise price of C$8.39 using an exchange rate of C$1.40 = US$1.00. The options expire on October 1, 2035, and according to the filing vest quarterly over two years commencing on December 31, 2025.

The filing also reports 25,000 Restricted Share Units held directly by Lewis-Hall. The filing states each RSU represents a right to receive one Helus Pharma common share, with vesting scheduled for November 20, 2026. No amendments to a prior Form 3 are indicated, confirming this is an initial filing rather than a revision.

What Was Disclosed

Freda C. Lewis-Hall's Form 3 discloses an initial beneficial ownership position in Helus Pharma Inc. comprising 100,000 direct common shares, 25,000 indirectly held stock options through Intelmed, LLC, and 25,000 directly held RSUs, as of October 13, 2026.